Abbisko and Sperogenix Announce An Exclusive Agreement to Develop ABSK021 for ALS and Other Rare Neurological Diseases in Greater China ...Middle East

PR Newswire - News
Abbisko and Sperogenix Announce An Exclusive Agreement to Develop ABSK021 for ALS and Other Rare Neurological Diseases in Greater China
SHANGHAI, BEIJING, HONG KONG, July 4, 2021 /PRNewswire/ -- Sperogenix (Shanghai) MedTech Co., Ltd. ("Sperogenix"), a subsidiary of Sperogenix Therapeutics (platform company for development and commercialization of rare diseases medications in China), has entered into an exclusive...

Read More Details
Finally We wish PressBee provided you with enough information of ( Abbisko and Sperogenix Announce An Exclusive Agreement to Develop ABSK021 for ALS and Other Rare Neurological Diseases in Greater China )

Apple Storegoogle play

Also on site :